Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1025 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Synthesis and discovery of triazolo-pyridazine-6-yl-substituted piperazines as effective anti-diabetic drugs; evaluated over dipeptidyl peptidase-4 inhibition mechanism and insulinotropic activities
B. Bindu,S. Vijayalakshmi,A. Manikandan
European Journal of Medicinal Chemistry.2020;187()111912
[DOI]
2Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
Sandeep Chakraborty,Adela Rendón-Ramírez,Bjarni Ásgeirsson,Mouparna Dutta,Anindya S. Ghosh,Masataka Oda,Ravindra Venkatramani,Basuthkar J. Rao,Abhaya M. Dandekar,Félix M. Goñi
F1000Research.2013;2()286
[DOI]
3Long-term use of dipeptyl peptidase-4 inhibitors suppresses systemic oxidative stress in rats with type 2 diabetes
S. S. Bolevich,P. F. Litvitsky,V. Jakovljevic,S. B. Bolevich
Sechenov Medical Journal.2019;10(4)21
[DOI]
4The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy
Liberata Sportiello,Concetta Rafaniello,Cristina Scavone,Cristiana Vitale,Francesco Rossi,Annalisa Capuano
International Journal of Cardiology.2016;202(4)731
[DOI]
5DPP-4 inhibitor reduces striatal microglial deramification after sensorimotor cortex injury induced by external force impact
Yu-Wen Hung,Yun Wang,Sheau-Ling Lee
The FASEB Journal.2020;34(5)6950
[DOI]
6Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
Cristina Mega,Edite Teixeira-de-Lemos,Rosa Fernandes,Flávio Reis
Journal of Diabetes Research.2017;2017(5)1
[DOI]
7The Impact of a Large Bolus Dose of l-leucine and l-isoleucine on Enteroendocrine and Pancreatic Hormones, and Glycemia in Healthy, Inactive Adults
Daniel E. Newmire,Eric Rivas,Sarah E. Deemer,Darryn S. Willoughby,Victor Ben-Ezra
Nutrients.2019;11(11)2650
[DOI]
8Teneligliptin inhibits lipopolysaccharide-induced cytotoxicity and inflammation in dental pulp cells
Xin Liu,Yan Cao,Yan Zhang,Baozhen Sun,Haiying Liang
International Immunopharmacology.2019;73(11)57
[DOI]
9Vascular protection of DPP-4 inhibitors in retinal endothelial cells in in vitro culture
Heng Li,Junjun Zhang,Li Lin,Lishuai Xu
International Immunopharmacology.2019;66(11)162
[DOI]
10Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury
Zhen Zhang,Xiang Jin,Chunfeng Yang,Yumei Li
Biomedicine & Pharmacotherapy.2019;109(11)468
[DOI]
11Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus
Maurílio de Souza Cazarim,Estael Luzia Coelho da Cruz-Cazarim,André de Oliveira Baldoni,Thais Bueno Enes dos Santos,Paula Gonçalves de Souza,Ingrid de Almeida Silva,Roberta Niriam Reis Rodrigues,Alda Cristina Franco Correa Maia,Leonardo Régis Leira Pereira,Cristina Sanches
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2017;11(11)S859
[DOI]
12Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
Sandeep Chakraborty,Adela Rendón-Ramírez,Bjarni Ásgeirsson,Mouparna Dutta,Anindya S. Ghosh,Masataka Oda,Ravindra Venkatramani,Basuthkar J. Rao,Abhaya M. Dandekar,Félix M. Goñi
F1000Research.2015;2(11)286
[DOI]
13The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-?B
Suxia Ma,Zhifeng Bai,Huiying Wu,Wei Wang
European Journal of Pharmacology.2019;851(11)186
[DOI]
14Development of a gas chromatography–mass spectrometry method for the analysis of sitagliptin in human urine
Ebru Uçaktürk
Journal of Pharmaceutical and Biomedical Analysis.2013;74(11)71
[DOI]
15Alogliptin for the treatment of Type 2 diabetes
Yutaka Seino,Daisuke Yabe
Expert Review of Endocrinology & Metabolism.2014;9(6)547
[DOI]
16Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: R etrospective data for 10?256 individuals from the U nited K ingdom and G ermany
Kamlesh Khunti,Thomas R. Godec,Jesús Medina,Laura Garcia-Alvarez,Josh Hiller,Marilia B. Gomes,Javier Cid-Ruzafa,Bernard Charbonnel,Peter Fenici,Niklas Hammar,Kiyoshi Hashigami,Mikhail Kosiborod,Antonio Nicolucci,Marina V. Shestakova,Linong Ji,Stuart Pocock
Diabetes, Obesity and Metabolism.2018;20(2)389
[DOI]
17The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells
Feng-li Hao,Xiao-fang Han,Xiao-li Wang,Zhi-ru Zhao,Ai-hong Guo,Xin-jian Lu,Xiong-fei Zhao
Biomedicine & Pharmacotherapy.2019;109(2)181
[DOI]
18Comparison of charges and resource use associated with saxagliptin and sitagliptin
Varun Vaidya,Keyuri Adhikari,Jack Sheehan,Iftekhar Kalsekar
Health Economics Review.2016;6(1)181
[DOI]
19Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials
Khosro Keshavarz,Farhad Lotfi,Ehsan Sanati,Mahmood Salesi,Amir Hashemi-Meshkini,Mojtaba Jafari,Mohammad M. Mojahedian,Behzad Najafi,Shekoufeh Nikfar
DARU Journal of Pharmaceutical Sciences.2017;25(1)181
[DOI]
20DPP-4 inhibitors: pharmacological differences and their clinical implications
Antonio Ceriello,Liberata Sportiello,Concetta Rafaniello,Francesco Rossi
Expert Opinion on Drug Safety.2014;13(sup1)57
[DOI]
21The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
Sandeep Chakraborty,Adela Rendón-Ramírez,Bjarni Ásgeirsson,Mouparna Dutta,Anindya S. Ghosh,Masataka Oda,Ravindra Venkatramani,Basuthkar J. Rao,Abhaya M. Dandekar,Félix M. Goñi
F1000Research.2015;2(sup1)286
[DOI]
22Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013–2016) analysis
Christian Leporini,Rosanna Piro,Francesco Ursini,Francesca Maida,Caterina Palleria,Franco Arturi,Maria Pavia,Giovambattista De Sarro,Emilio Russo
Expert Opinion on Drug Safety.2016;15(sup2)17
[DOI]
23DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment
Momir Mikov,Nebojša Pavlovic,Bojan Stanimirov,Maja Ðanic,Svetlana Golocorbin-Kon,Karmen Stankov,Hani Al-Salami
European Journal of Drug Metabolism and Pharmacokinetics.2020;45(1)1
[DOI]
24Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
Erika Paniago Guedes,Alexandre Hohl,Thais Gomes de Melo,Felipe Lauand
Diabetology & Metabolic Syndrome.2013;5(1)1
[DOI]
25Computational Analysis of Gynura bicolor Bioactive Compounds as Dipeptidyl Peptidase-IV Inhibitor
Lina Rozano,Muhammad Redha Abdullah Zawawi,Muhamad Aizuddin Ahmad,Indu Bala Jaganath
Advances in Bioinformatics.2017;2017(1)1
[DOI]
26Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)
Sujoy Ghosh,Mangesh Tiwaskar,Rajiv Chawla,Shalini Jaggi,Arthur Asirvatham,Vijay Panikar
Diabetes Therapy.2020;11(10)2257
[DOI]
27Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemia–reperfusion injury in rats with diabetes mellitus type 2
Jovana Bradic,Isidora Milosavljevic,Stefani Bolevich,Peter F Litvitskiy,Nevena Jeremic,Sergey Bolevich,Vladimir Zivkovic,Ivan Srejovic,Jovana Jeremic,Nemanja Jovicic,Slobodanka Mitrovic,Vladimir Jakovljevic
Clinical and Experimental Pharmacology and Physiology.2020;11(10)2257
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal